本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Altamira Therapeutics Ltd.

0.3000
0.0000
成交量:- -
成交额:- -
市值:113.36万
市盈率:-0.16
高:0.3000
开:0.3000
低:0.3000
收:0.3000
52周最高:3.60
52周最低:0.3000
股本:377.85万
流通股本:375.78万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.9065
每股收益(LYR):-9.3533
净资产收益率:-368.78%
总资产收益率:-57.15%
市净率:0.18
市盈率(LYR):-0.03

数据加载中...

2024/11/14

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/09/17

SEC问询函

Form CORRESP - Correspondence
2024/09/17

SEC问询函

Form CORRESP - Correspondence
2024/09/16

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/09/16

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2024/08/22

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/07/01

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2024/04/22

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2024/04/17

SEC问询函

Form CORRESP - Correspondence
2024/04/10

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/10

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/04/10

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/03/13

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/17

SEC问询函

Form CORRESP - Correspondence
2023/07/05

SEC问询函

Form CORRESP - Correspondence
2023/07/05

SEC问询函

Form CORRESP - Correspondence
2023/07/05

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2023/06/16

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2023/06/09

SEC问询函

Form CORRESP - Correspondence
2023/06/09

SEC问询函

Form CORRESP - Correspondence